Association of Hospital Resource Utilization With Neurodevelopmental Outcomes in Neonates With Hypoxic-Ischemic Encephalopathy.
Journal
JAMA network open
ISSN: 2574-3805
Titre abrégé: JAMA Netw Open
Pays: United States
ID NLM: 101729235
Informations de publication
Date de publication:
01 03 2023
01 03 2023
Historique:
entrez:
21
3
2023
pubmed:
22
3
2023
medline:
24
3
2023
Statut:
epublish
Résumé
Intercenter variation exists in the management of hypoxic-ischemic encephalopathy (HIE). It is unclear whether increased resource utilization translates into improved neurodevelopmental outcomes. To determine if higher resource utilization during the first 4 days of age, quantified by hospital costs, is associated with survival without neurodevelopmental impairment (NDI) among infants with HIE. Retrospective cohort analysis of neonates with HIE who underwent therapeutic hypothermia (TH) at US children's hospitals participating in the Children's Hospitals Neonatal Database between 2010 and 2016. Data were analyzed from December 2021 to December 2022. Infants who survived to 4 days of age and had neurodevelopmental outcomes assessed at greater than 11 months of age were divided into 2 groups: (1) death or NDI and (2) survived without NDI. Resource utilization was defined as costs of hospitalization including neonatal neurocritical care (NNCC). Data were linked with Pediatric Health Information Systems to quantify standardized costs by terciles. The main outcome was death or NDI. Characteristics, outcomes, hospitalization, and NNCC costs were compared. Among the 381 patients who were included, median (IQR) gestational age was 39 (38-40) weeks; maternal race included 79 (20.7%) Black mothers, 237 (62.2%) White mothers, and 58 (15.2%) mothers with other race; 80 (21%) died, 64 (17%) survived with NDI (combined death or NDI group: 144 patients [38%]), and 237 (62%) survived without NDI. The combined death or NDI group had a higher rate of infants with Apgar score at 10 minutes less than or equal to 5 (65.3% [94 of 144] vs 39.7% [94 of 237]; P < .001) and a lower rate of infants with mild or moderate HIE (36.1% [52 of 144] vs 82.3% [195 of 237]; P < .001) compared with the survived without NDI group. Compared with low-cost centers, there was no association between high- or medium-hospitalization cost centers and death or NDI. High- and medium-EEG cost centers had lower odds of death or NDI compared with low-cost centers (high vs low: OR, 0.30 [95% CI, 0.16-0.57]; medium vs low: OR, 0.29 [95% CI, 0.13-0.62]). High- and medium-laboratory cost centers had higher odds of death or NDI compared with low-cost centers (high vs low: OR, 2.35 [95% CI, 1.19-4.66]; medium vs low: OR, 1.93 [95% CI, 1.07-3.47]). High-antiseizure medication cost centers had higher odds of death or NDI compared with low-cost centers (high vs. low: OR, 3.72 [95% CI, 1.51-9.18]; medium vs low: OR, 1.56 [95% CI, 0.71-3.42]). Hospitalization costs during the first 4 days of age in neonates with HIE treated with TH were not associated with neurodevelopmental outcomes. Higher EEG costs were associated with lower odds of death or NDI yet higher laboratory and antiseizure medication costs were not. These findings serve as first steps toward identifying aspects of NNCC that are associated with outcomes.
Identifiants
pubmed: 36943267
pii: 2802680
doi: 10.1001/jamanetworkopen.2023.3770
pmc: PMC10031395
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e233770Investigateurs
Nathalie Maitre
(N)
Amit Mathur
(A)
Eugenia Pallotto
(E)
Danielle Smith
(D)
Mark Speziale
(M)
Toby Yanowitz
(T)
Beverly Brozanski
(B)
Jacquelyn Evans
(J)
Theresa Grover
(T)
Karna Murthy
(K)
Michael Padula
(M)
Anthony Piazza
(A)
Kristina Reber
(K)
Billie Short
(B)
David Durand
(D)
Francine Dykes
(F)
Jeanette Asselin
(J)
Kevin Sullivan
(K)
Victor McKay
(V)
Jamie Limjoco
(J)
Lori Haack
(L)
Narenda Dereddy
(N)
Raj Wadhawan
(R)
Gustave Falciglia
(G)
Becky Rogers
(B)
Anne Hansen
(A)
Cherrie Welch
(C)
Beth Haberman
(B)
Gregory Sysyn
(G)
Nicole Birge
(N)
THeresa Grover
(T)
Michel Mikhael
(M)
Irfan Ahmad
(I)
David Munson
(D)
Michael Uhing
(M)
Ankur Datta
(A)
Rashmin Savani
(R)
Luc Brion
(L)
Julie Weiner
(J)
Lamia Soghier
(L)
Carl Coghill
(C)
Allison Black
(A)
Steven Chin
(S)
Rachel Chapman
(R)
AnneMarie Golioto
(A)
Jonathan Nedrelow
(J)
Annie Chi
(A)
Yvette Johnson
(Y)
Mark Weems
(M)
Aaron Weiss
(A)
Trent Tripple
(T)
Con Yee Ling
(CY)
Shrena Patel
(S)
Brian Lane
(B)
Laurel Moyer
(L)
William Engle
(W)
Lora Simpson
(L)
Gregory Sokol
(G)
Elizabeth Jacobsen-Misbe
(E)
Julie Lindower
(J)
Gautham Suresh
(G)
Lakshmi Khatakam
(L)
Art D'Harlingue
(A)
Références
J Pediatr. 2016 Jun;173:76-83.e1
pubmed: 26995699
Curr Probl Pediatr. 1996 Sep;26(8):279-306
pubmed: 8899289
N Engl J Med. 2005 Oct 13;353(15):1574-84
pubmed: 16221780
Am Heart J. 2010 Dec;160(6):1099-104
pubmed: 21146664
Dev Med Child Neurol. 2016 Dec;58(12):1242-1248
pubmed: 27595841
Clin Pediatr (Phila). 1995 May;34(5):248-55
pubmed: 7543037
J Perinatol. 2015 Apr;35(4):290-6
pubmed: 25393081
J Pediatr. 2022 Apr;243:61-68.e2
pubmed: 34626667
J Pediatr. 2009 Sep;155(3):318-23
pubmed: 19540512
Semin Fetal Neonatal Med. 2015 Jun;20(3):149-53
pubmed: 25660396
J Child Neurol. 2009 Feb;24(2):148-54
pubmed: 19182150
J Matern Fetal Neonatal Med. 2022 Mar;35(5):890-897
pubmed: 32156180
J Neurosci. 2001 Mar 15;21(6):2094-103
pubmed: 11245693
BMC Pediatr. 2019 Feb 27;19(1):67
pubmed: 30813933
Arch Pediatr Adolesc Med. 2012 Dec;166(12):1155-64
pubmed: 23027409
J Perinatol. 2014 Oct;34(10):736-40
pubmed: 25144157
J Child Neurol. 2011 Mar;26(3):322-8
pubmed: 20921569
J Clin Neurophysiol. 2011 Dec;28(6):611-7
pubmed: 22146359
J Child Neurol. 2011 Jun;26(6):724-8
pubmed: 21447810
Curr Probl Pediatr. 1996 Aug;26(7):238-57
pubmed: 8889388
Neuroscience. 2010 Mar 10;166(1):157-67
pubmed: 20006975
JAMA Netw Open. 2021 Dec 1;4(12):e2139604
pubmed: 34919132
J Pediatr. 2011 Nov;159(5):731-735.e1
pubmed: 21839470
N Engl J Med. 2014 Jul 10;371(2):140-9
pubmed: 25006720
Pediatrics. 2021 Feb;147(2):
pubmed: 33452064
JAMA Netw Open. 2021 Dec 1;4(12):e2140677
pubmed: 34919137
J Pediatr Neurosci. 2016 Oct-Dec;11(4):309-315
pubmed: 28217152
J Child Neurol. 2011 Apr;26(4):532; author reply 533-4
pubmed: 21493809
Pediatrics. 2015 Nov;136(5):e1302-9
pubmed: 26482675
Semin Fetal Neonatal Med. 2021 Oct;26(5):101303
pubmed: 34711527
Dev Neurosci. 2017;39(1-4):82-88
pubmed: 28081533
J Perinatol. 2022 Jul;42(7):898-906
pubmed: 35552529
Epilepsia. 2016 May;57(5):727-34
pubmed: 27012547
Pediatr Res. 2001 Mar;49(3):320-5
pubmed: 11228256
J Perinatol. 2014 Aug;34(8):582-6
pubmed: 24603454
Pediatrics. 2018 May;141(5):
pubmed: 29666163
Proc Natl Acad Sci U S A. 2002 Nov 12;99(23):15089-94
pubmed: 12417760
Am J Perinatol. 2018 Aug;35(10):951-958
pubmed: 29452428
Pediatr Neurol. 2019 Feb;91:20-26
pubmed: 30559002